Logo 1 Logo 2

Clinical Trial Details

Trial ID: L3663
Source ID: NCT01691846
Associated Drug: Aleglitazar+Metformin
Title: A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus Type 2
Interventions: DRUG: aleglitazar+metformin|DRUG: placebo+metformin
Outcome Measures: Primary: Change from baseline in hemoglobin HbA1c, From baseline to week 26 | Secondary: Change in lipid profile, From baseline to week 26|Change from baseline in fasting plasma glucose, From baseline to week 26|Responder rate as defined of hemoglobin HbAc1 <7.0% (<6.5%), From baseline to week 26|Change from baseline in homeostatic index of insulin sensitivity (HOMA-IS), From baseline to week 26|Change from baseline in homeostatic index of beta cell function (HOMA-BCF), From baseline to week 26|Safety: incidence of adverse events, 30 weeks (26 weeks treatment and 4 weeks follow-up)
Sponsor/Collaborators: Sponsor: Hoffmann-La Roche
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 200
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2012-10
Completion Date: 2013-09
Results First Posted:
Last Update Posted: 2017-02-23
Locations: Chino, California, 91710, United States|Hawaiian Gardens, California, 90716, United States|Los Angeles, California, 90057, United States|Santa Ana, California, 92701, United States|Thousand Oaks, California, 91360, United States|West Hills, California, 91307, United States|Kissimmee, Florida, 34741, United States|Atlanta, Georgia, 30338, United States|Chicago, Illinois, 60607, United States|Avon, Indiana, 46123, United States|Bethesda, Maryland, 20817, United States|Springfield, Missouri, 65807, United States|Toms River, New Jersey, 08753, United States|Altoona, Pennsylvania, 16602, United States|Beaver, Pennsylvania, 15009, United States|Morrisville, Pennsylvania, 19067, United States|Scranton, Pennsylvania, 18510, United States|Tipton, Pennsylvania, 16684, United States|Knoxville, Tennessee, 37919, United States|Dallas, Texas, 75230, United States|Richmond, Virginia, 23249, United States|Spokane, Washington, 99202, United States|Buenos Aires, 1056, Argentina|Caba, C1428DCO, Argentina|Rosario, S2000CXP, Argentina|Cuernavaca, 62250, Mexico|Culiacan, 80020, Mexico|Guadalajara, 44650, Mexico|Mexico City, 11650, Mexico|Pachuca, 42060, Mexico|Tampico, 89000, Mexico
URL: https://clinicaltrials.gov/show/NCT01691846